Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab + erlotinib extension study in advanced non-small cell lung cancer
2013-000104-42Phase 2Completed
- Sponsor
- Daiichi Sankyo Development
- Start
- Apr 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patritumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Development. Primary endpoint: Safety. Started Apr 2013; status: completed.
02
Drugs
patritumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-000104-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000104-42.